Beximco Pharma Regulatory News (BXP)

15 Oct 2009 13:58



BEXIMCO PHARMACEUTICALS LTD.

15th October, 2009

Extra-Ordinary General Meeting Statement

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announces that all resolutions put before shareholders at today's Extra-Ordinary General Meeting were duly passed. 

Further information in respect of the Preference Share Issue announced on 10 September 2009, including progress on the Bangladesh SEC approval process, will be announced shortly.

For further enquiries please visit www.beximco-pharma.com or contact:

Beximco Pharma

Nazmul Hassan, CEO

MD. ASAD ULLAH, FCS, Company Secretary

Tel: +880 2 861 9151, ext.2080

Libertas Capital

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.